We look back to a long history in biopharmaceuticals development and manufacturing. We’ve been one of the first companies in Europe which invested in large-scale facilities for manufacturing of biopharmaceutical medicines. With the growing need for such therapies in the late 1990‘s we started to...
We look back to a long history in biopharmaceuticals development and manufacturing. We’ve been one of the first companies in Europe which invested in large-scale facilities for manufacturing of biopharmaceutical medicines. With the growing need for such therapies in the late 1990‘s we started to...
We look back to a long history in biopharmaceuticals development and manufacturing. We’ve been one of the first companies in Europe which invested in large-scale facilities for manufacturing of biopharmaceutical medicines. With the growing need for such therapies in the late 1990‘s we started to...
We look back to a long history in biopharmaceuticals development and manufacturing. We’ve been one of the first companies in Europe which invested in large-scale facilities for manufacturing of biopharmaceutical medicines. With the growing need for such therapies in the late 1990‘s we started to...
We look back to a long history in biopharmaceuticals development and manufacturing. We’ve been one of the first companies in Europe which invested in large-scale facilities for manufacturing of biopharmaceutical medicines. With the growing need for such therapies in the late 1990‘s we started to...
The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres Sustainability at AstraZeneca Corporate Press Release Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn ...
At Pfizer, we believe that everyone should have the same opportunity to access the latest advances in cancer care, regardless of their background or where they live. That’s why we’re proud to partner with the American Cancer Society on “Change the Odds: Uniting to Improve Cancer Outcomes...
The biopharmaceutical industry in Uzbekistan Commercial and technological opportunities for UK companiesRimmington, ACarr, BAsbridge, S.M
Biopharmaceutical companies need to rethink their approach to clinical and economic value. Taking a structured approach will help uncover stakeholders’ questions and knowledge gaps at the earliest phases of clinical development. By collaborating cross-functionally, manufacturers can build a holis...
First, a dynamic data envelopment analysis model is adopted to evaluate the performance of the U.S. biopharmaceutical companies. Then, ordinary least squares regression is used to explore the effects of three patent‐related variables (patent counts, citations, and claims) and R&D spikes on ...